Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

Peter Wipfler; Katrin Oppermann; Georg Pilz; S Afazel; Elisabeth Haschke-Becher; Andrea Harrer; Michael Huemer; Alexander Kunz; Stefan Golaszewski; Wolfgang Staffen; G Ladurner; Jörg Kraus

doi:10.1177/1352458510383075

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

Peter Wipfler^* (First author)
, Katrin Oppermann (Co-author)
, Georg Pilz (Co-author)
, S Afazel
, Elisabeth Haschke-Becher (Co-author)
, Andrea Harrer (Co-author)
, Michael Huemer (Co-author)
, Alexander Kunz
, Stefan Golaszewski (Co-author)
, Wolfgang Staffen (Co-author)
, G Ladurner
, Jörg Kraus (Last author)

^*Corresponding author for this work

Department of Neurology
Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

28 Citations (Web of Science)

Original language	English
Pages (from-to)	16-23
Journal	MULTIPLE SCLEROSIS
Volume	17
Issue number	1
DOIs	https://doi.org/10.1177/1352458510383075
Publication status	Published - 2011

Keywords

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
BLOOD-BRAIN-BARRIER
MULTIPLE-SCLEROSIS LESIONS
NERVOUS-SYSTEM
CEREBROSPINAL-FLUID
LFA-1
INTEGRIN

Access to Document

10.1177/1352458510383075

Cite this

Wipfler, P., Oppermann, K., Pilz, G., Afazel, S., Haschke-Becher, E., Harrer, A., Huemer, M., Kunz, A., Golaszewski, S., Staffen, W., Ladurner, G., & Kraus, J. (2011). Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. MULTIPLE SCLEROSIS , 17(1), 16-23. https://doi.org/10.1177/1352458510383075

Wipfler, Peter ; Oppermann, Katrin ; Pilz, Georg et al. / Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. In: MULTIPLE SCLEROSIS 2011 ; Vol. 17, No. 1. pp. 16-23.

@article{d49ecf71aae647808219a05c752a54d1,

title = "Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.",

keywords = "EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, BLOOD-BRAIN-BARRIER, MULTIPLE-SCLEROSIS LESIONS, NERVOUS-SYSTEM, CEREBROSPINAL-FLUID, LFA-1, INTEGRIN",

author = "Peter Wipfler and Katrin Oppermann and Georg Pilz and S Afazel and Elisabeth Haschke-Becher and Andrea Harrer and Michael Huemer and Alexander Kunz and Stefan Golaszewski and Wolfgang Staffen and G Ladurner and J{\"o}rg Kraus",

note = " P Wipfler1 K Oppermann1 G Pilz1 S Afazel1 E Haschke-Becher1 A Harrer1 M Huemer2 A Kunz1 S Golaszewski1 W Staffen1 G Ladurner1 J Kraus1 1Paracelsus Medical University, Christian-Doppler-Klinik, University Hospital of Neurology, Salzburg, Austria. 2Kardinal-Schwarzenberg{\textquoteright}sches Krankenhaus, Department of Neurology, Schwarzach im Pongau, Austria. ",

year = "2011",

doi = "10.1177/1352458510383075",

language = "English",

volume = "17",

pages = "16--23",

journal = "MULTIPLE SCLEROSIS ",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "1",

}

Wipfler, P, Oppermann, K, Pilz, G, Afazel, S, Haschke-Becher, E, Harrer, A, Huemer, M, Kunz, A, Golaszewski, S, Staffen, W, Ladurner, G & Kraus, J 2011, 'Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.', MULTIPLE SCLEROSIS , vol. 17, no. 1, pp. 16-23. https://doi.org/10.1177/1352458510383075

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. / Wipfler, Peter (First author); Oppermann, Katrin (Co-author); Pilz, Georg (Co-author) et al.
In: MULTIPLE SCLEROSIS , Vol. 17, No. 1, 2011, p. 16-23.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

AU - Wipfler, Peter

AU - Oppermann, Katrin

AU - Pilz, Georg

AU - Afazel, S

AU - Haschke-Becher, Elisabeth

AU - Harrer, Andrea

AU - Huemer, Michael

AU - Kunz, Alexander

AU - Golaszewski, Stefan

AU - Staffen, Wolfgang

AU - Ladurner, G

AU - Kraus, Jörg

N1 - P Wipfler1 K Oppermann1 G Pilz1 S Afazel1 E Haschke-Becher1 A Harrer1 M Huemer2 A Kunz1 S Golaszewski1 W Staffen1 G Ladurner1 J Kraus1 1Paracelsus Medical University, Christian-Doppler-Klinik, University Hospital of Neurology, Salzburg, Austria. 2Kardinal-Schwarzenberg’sches Krankenhaus, Department of Neurology, Schwarzach im Pongau, Austria.

PY - 2011

Y1 - 2011

KW - EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

KW - BLOOD-BRAIN-BARRIER

KW - MULTIPLE-SCLEROSIS LESIONS

KW - NERVOUS-SYSTEM

KW - CEREBROSPINAL-FLUID

KW - LFA-1

KW - INTEGRIN

U2 - 10.1177/1352458510383075

DO - 10.1177/1352458510383075

M3 - Original Article

C2 - 20937631

SN - 1352-4585

VL - 17

SP - 16

EP - 23

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 1

ER -

Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A et al. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. MULTIPLE SCLEROSIS . 2011;17(1):16-23. doi: 10.1177/1352458510383075